DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally
Summarize this article with:
Bret JensenInvesting Group LeaderFollow5ShareSavePlay(6min)CommentsSummaryToday, I highlight a clinical-stage biopharma focused on allergy immunotherapies called DBV Technologies.Viaskin Peanut, DBVT's lead asset, is being evaluated in two Phase 3 trials targeting peanut allergies.The company's balance sheet is in good stead with a recent capital raise, the stock has seen a big recent rally, and potential FDA approval looms in 2026.An analysis around DBV Technologies follows in the paragraphs below.CalypsoArt/iStock via Getty Images Today, I am putting DBV Technologies S.A. (DBVT) in the spotlight. The company is based overseas and therefore gets relatively little coverage from Wall Street. The company is moving towards filing a key marketing application early nextThis article was written byBret Jensen54.82K FollowersFollowBret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You